ArticleCell research2026
Asymmetric division rejuvenates stem cell lineages.
Jianlong Wang
Abstract read
In one paragraphArticle in Cell research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
1 author.
Jianlong WangDepartment of Medicine, Columbia Center for Human Development, Columbia Center for Stem Cell Therapies, Columbia Stem Cell Initiative, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA. jw3925@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-1317-6457 Funding
Therapeutic value and mechanistic action of PSPC1 in AMLR01CA285299 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jianlong Wang, Mingjiang Xu · 2024 to 2026
$3.0MRNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cellsR01HD095938 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, JIANLONG · 2018 to 2022
$1.7MDefining Novel Molecular Pathways to TotipotencyR01HD097268 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, JIANLONG · 2018 to 2022
$1.7MTET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesisR01HL146664 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WANG, JIANLONG, XU, MINGJIANG · 2019 to 2022
$1.7MA Nucleolar Paradigm for Pluripotency of Human Embryonic Stem CellsR01HD114122 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jianlong Wang · 2024 to 2026
$1.6MDecoding NSUN2-mediated translational control of pluripotent stem cellsR21HD116446 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WANG, JIANLONG · 2024 to 2025
$452kU.S. Department of Defense (United States Department of Defense) BC200469U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R01HD095938U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R01HD097268U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R01HD114122U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R21HD116446U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA285299U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL146664
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID41692871
PMCPMC13013559
What OpenQuestion holds
Textmetadata
Read underepoch 390